ADMINISTRATION The Consortium Administration provides high quality, efficient, and effective support to Fred Hutch/University of Washington Cancer Consortium leaders, Research Programs, Shared Resources, and members. Administration owns and drives the processes that Consortium scientific leaders use to define the Consortium's vision and strategic goals, implement initiatives, monitor progress in achieving objectives, and secure needed resources to develop and maintain the requisite infrastructure. Consortium Director Dr. Gary Gilliland and senior leaders developed a strategic plan through a process started when he arrived in 2015. The process is ongoing by design with annual internal and external evaluations of milestones. Throughout the process Administration ensures that CCSG guidelines are integral to the strategic goals and activities. As a result of these activities, Consortium membership has grown by >170 members; cancer-relevant grant funding for the Consortium is at $242M, of which $50M is from the NCI; interventional trials have 5,424 accruals and non-interventional trials have 5,292 accruals (increases of 83% and 20%, respectively, from FY 2014 to FY 2018); and members have over 6,600 cancer-related publications as authors and co-authors, with 11% of them in journals with impact factors greater than 20. New in this cycle of the CCSG are the components for Community Outreach & Engagement (COE) and Cancer Research Career Enhancement (CRCE). Administration has been pivotal to establishing offices for both of these new components to oversee their respective areas of activity. Other new Consortium initiatives include the formation of three Integrated Research Centers (IRCs), the continued development of the Seattle Translational Tumor Research initiative (STTR), and major enhancements of clinical trials infrastructure. Administration has interfaced with initiative leaders and their respective administrators in order to leverage strengths and resources toward supporting Research Programs and members. Finally, as a result of faculty feedback, a new developing Shared Resource for preclinical mouse models was developed by Administration to further Consortium science. `

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411

Showing the most recent 10 out of 1267 publications